The announcement means the company will be pulling the plug on the CardinALS trial after its amyotrophic lateral sclerosis ...

But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show if twice daily oral dosing of ...

A team from IIT-BHU is developing a revolutionary cell-based device using 3D bioprinting technology to potentially cure ...

PTC Therapeutics may reeling from the failure of its amyotrophic lateral sclerosis (ALS) drug utreloxastat yesterday, but the ...

A team at IIT (BHU) is developing a revolutionary cell-based medical device using 3D bioprinting technology aimed at curing ...

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral ...

Widetrial is supporting an expanded access program (EAP) to bring MN-166 (ibudilast) to ALS patients ineligible for clinical ...

ALS is a progressive neurodegenerative disease — and there is no cure. Brunner, who was running 3 miles a day at the onset of ...

PTC Therapeutics will scrap development of its treatment for amyotrophic lateral sclerosis after it failed to meet a primary endpoint in a Phase 2 trial.

The Converge platform validated as many as 83% of its treatment targets in disease models, a higher success rate than usual ...

PTC Therapeutics said on Tuesday its drug did not meet the main goal in a mid-stage trial evaluating it in patients with a type of fatal neurodegenerative disease called amyotrophic lateral sclerosis.

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage ...